TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07864701: A Phase I/II Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity and Efficacy of JMBI-001 Tablets in Participants With MYC-Positive Advanced Solid Tumors or Relapsed/Refractory No

Sponsor: Chengdu Anticancer Bioscience, Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07864701 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07864701 Rescue Dossier →